Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(50%)

Phase Distribution

Ph phase_3
2
100%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution2 total trials
Phase 3Large-scale testing
2(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Terminated(1)
Other(1)

Detailed Status

unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 32 (100.0%)

Trials by Status

unknown150%
terminated150%

Recent Activity

0 active trials
Showing 2 of 2
unknownphase_3

Study of Combined Topical Growth Factor and Protease Inhibitor in Chronic Wound Healing

NCT02845466
terminatedphase_3

A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX

NCT00034788

Clinical Trials (2)

Showing 2 of 2 trials
NCT02845466Phase 3

Study of Combined Topical Growth Factor and Protease Inhibitor in Chronic Wound Healing

Unknown
NCT00034788Phase 3

A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX

Terminated

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2